Unlocking c-MET : A comprehensive journey into targeted therapies for breast cancer
Copyright © 2024 Elsevier B.V. All rights reserved..
Breast cancer is the most common malignancy among women, posing a formidable health challenge worldwide. In this complex landscape, the c-MET (cellular-mesenchymal epithelial transition factor) receptor tyrosine kinase (RTK), also recognized as the hepatocyte growth factor (HGF) receptor (HGFR), emerges as a prominent protagonist, displaying overexpression in nearly 50% of breast cancer cases. Activation of c-MET by its ligand, HGF, secreted by neighboring mesenchymal cells, contributes to a cascade of tumorigenic processes, including cell proliferation, metastasis, angiogenesis, and immunosuppression. While c-MET inhibitors such as crizotinib, capmatinib, tepotinib and cabozantinib have garnered FDA approval for non-small cell lung cancer (NSCLC), their potential within breast cancer therapy is still undetermined. This comprehensive review embarks on a journey through structural biology, multifaceted functions, and intricate signaling pathways orchestrated by c-MET across cancer types. Furthermore, we highlight the pivotal role of c-MET-targeted therapies in breast cancer, offering a clinical perspective on this promising avenue of intervention. In this pursuit, we strive to unravel the potential of c-MET as a beacon of hope in the fight against breast cancer, unveiling new horizons for therapeutic innovation.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:588 |
---|---|
Enthalten in: |
Cancer letters - 588(2024) vom: 28. Apr., Seite 216780 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Jabbarzadeh Kaboli, Parham [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 09.04.2024 Date Revised 09.04.2024 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.canlet.2024.216780 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM369517598 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM369517598 | ||
003 | DE-627 | ||
005 | 20240409232609.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240311s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.canlet.2024.216780 |2 doi | |
028 | 5 | 2 | |a pubmed24n1370.xml |
035 | |a (DE-627)NLM369517598 | ||
035 | |a (NLM)38462033 | ||
035 | |a (PII)S0304-3835(24)00173-3 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Jabbarzadeh Kaboli, Parham |e verfasserin |4 aut | |
245 | 1 | 0 | |a Unlocking c-MET |b A comprehensive journey into targeted therapies for breast cancer |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 09.04.2024 | ||
500 | |a Date Revised 09.04.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2024 Elsevier B.V. All rights reserved. | ||
520 | |a Breast cancer is the most common malignancy among women, posing a formidable health challenge worldwide. In this complex landscape, the c-MET (cellular-mesenchymal epithelial transition factor) receptor tyrosine kinase (RTK), also recognized as the hepatocyte growth factor (HGF) receptor (HGFR), emerges as a prominent protagonist, displaying overexpression in nearly 50% of breast cancer cases. Activation of c-MET by its ligand, HGF, secreted by neighboring mesenchymal cells, contributes to a cascade of tumorigenic processes, including cell proliferation, metastasis, angiogenesis, and immunosuppression. While c-MET inhibitors such as crizotinib, capmatinib, tepotinib and cabozantinib have garnered FDA approval for non-small cell lung cancer (NSCLC), their potential within breast cancer therapy is still undetermined. This comprehensive review embarks on a journey through structural biology, multifaceted functions, and intricate signaling pathways orchestrated by c-MET across cancer types. Furthermore, we highlight the pivotal role of c-MET-targeted therapies in breast cancer, offering a clinical perspective on this promising avenue of intervention. In this pursuit, we strive to unravel the potential of c-MET as a beacon of hope in the fight against breast cancer, unveiling new horizons for therapeutic innovation | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Review | |
650 | 4 | |a Breast cancer | |
650 | 4 | |a Clinical approach | |
650 | 4 | |a Hepatocyte growth factor receptor | |
650 | 4 | |a Targeted therapy | |
650 | 4 | |a Tumorigenesis | |
650 | 4 | |a c-MET receptor | |
650 | 7 | |a Hepatocyte Growth Factor |2 NLM | |
650 | 7 | |a 67256-21-7 |2 NLM | |
650 | 7 | |a Proto-Oncogene Proteins c-met |2 NLM | |
650 | 7 | |a EC 2.7.10.1 |2 NLM | |
700 | 1 | |a Chen, Hsiao-Fan |e verfasserin |4 aut | |
700 | 1 | |a Babaeizad, Ali |e verfasserin |4 aut | |
700 | 1 | |a Roustai Geraylow, Kiarash |e verfasserin |4 aut | |
700 | 1 | |a Yamaguchi, Hirohito |e verfasserin |4 aut | |
700 | 1 | |a Hung, Mien-Chie |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Cancer letters |d 1976 |g 588(2024) vom: 28. Apr., Seite 216780 |w (DE-627)NLM000147273 |x 1872-7980 |7 nnns |
773 | 1 | 8 | |g volume:588 |g year:2024 |g day:28 |g month:04 |g pages:216780 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.canlet.2024.216780 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 588 |j 2024 |b 28 |c 04 |h 216780 |